The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | GIANT: chemotherapy regimens in elderly patients with mPDAC
Efrat Dotan, MD, Fox Chase Cancer Center, Philadelphia, PA, explores the Phase II GIANT trial (NCT04233866), which investigated the best treatment strategy for vulnerable older adults (≥70 years) with newly diagnosed metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients received either gemcitabine with nab-paclitaxel or 5-fluorouracil with leucovorin and liposomal irinotecan. Results revealed no significant difference in overall survival between the regimens, providing critical data to inform treatment choices for this vulnerable group. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Agenus; Amgen; G1 Therapeutics; Incyte; Olympus; Taiho Pharmaceutical
Research Funding – Dragonfly Therapeutics (Inst); Gilead Sciences (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses – Olympus
